Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 3, 2010, Pages 270-277

  Grebely, Jason ^a   Knight, Elizabeth ^b   Genoway, Krista A ^d   Viljoen, Mark ^c   Khara, Milan ^c   Elliott, Doug ^c   Gallagher, Lesley ^b   Storms, Michelle ^b   Raffa, Jesse D ^d   Devlaming, Stanley ^c   Duncan, Fiona ^c   Conway, Brian ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Pender Community Health Centre   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Assessment; Hepatitis C virus; Illicit drug users; Injection drug users; Treatment

Indexed keywords

ILLICIT DRUG; METHADONE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMORBIDITY; DRUG DEPENDENCE; DRUG USE; FEMALE; FOLLOW UP; HEALTH CENTER; HEPATITIS C; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REFERRAL; PEER GROUP; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG CARRIERS; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERFERONS; MALE; MEDICAL RECORDS; MIDDLE AGED; ODDS RATIO; PATIENT CARE TEAM; PEER GROUP; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; SELF-HELP GROUPS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 76649140825     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832a8c4c     Document Type: Article

References (40)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
2. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001; 165:889-895.
3. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 91:23-30.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1):S35-S46.
5. NCHECR. HIV/AIDS, Viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2003. Sydney: National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales, 2003.
6. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (London, England) 2006; 20:2361-2369.
7. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-133.
8. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus (HCV) infection in a large community-based cohort of illicit drug users in Vancouver. J Viral Hepatitis 2009 [Epub ahead of print]
9. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36 (5 Suppl 1):S210-S219.
10. Treloar C, Holt M. Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev 2008; 32:570-576.
11. Van Thiel DH, Molloy PJ, Friedlander L, Kania RJ, Fagiuoli S, Caraceni P, et al. Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. Hepatogastroenterology 1995; 42:900-906.
12. Backmund M, Meyer K,Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193.
13. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40 (Suppl 5):S336-S338.
14. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-123.
15. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24:1627-1635.
16. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
17. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-2288.
18. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124.
19. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40 (Suppl 5):S325-S329.
20. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29:159-165.
21. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18:159-166.
22. Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45:111-117.
23. Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification program. Addiction (Abingdon, England) 2007; 102:423-431.
24. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22:1519-1525.
25. Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. The International journal on drug policy 2007; 18:437-443.
26. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in difficult-to-treat psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46:991-998.
27. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-1543.
28. Grebely J, Raffa J, Genoway K, Showler G, Duncan F, Viljoen M, et al. Infrequent hepatitis C virus (HCV) re-infection after sustained virological response (SVR) among current and former injection drug users (IDUs) having received treatment for HCV infection [Abstract 296]. Hepatology 2007; 46:370A.
29. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. The Int J Drug Policy 2007; 18:406-410.
30. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004; 37:1367-1375.
31. Restrepo A, Johnson TC, Widjaja D, Yarmus L, Meyer K, Clain DJ, et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005; 12:86-90.
32. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
33. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-292.
34. Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40 (Suppl 5):S304-S312.
35. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93:141-147.
36. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40 (Suppl 5):S313-S320.
37. Fischer B, Vasdev S, Haydon E, Baliunas D, Rehm J. Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada. Presse Med 2005; 34:1209-1212.
38. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347:975-982.
39. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
40. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007; 13:216-221.